<SEC-DOCUMENT>0001193125-20-242879.txt : 20200910
<SEC-HEADER>0001193125-20-242879.hdr.sgml : 20200910
<ACCEPTANCE-DATETIME>20200910124829
ACCESSION NUMBER:		0001193125-20-242879
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200910
FILED AS OF DATE:		20200910
DATE AS OF CHANGE:		20200910

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Theratechnologies Inc.
		CENTRAL INDEX KEY:			0001512717
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A8
		FISCAL YEAR END:			1130

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35203
		FILM NUMBER:		201168239

	BUSINESS ADDRESS:	
		STREET 1:		2015 PEEL STREET
		STREET 2:		5TH FLOOR
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H3A 1T8
		BUSINESS PHONE:		514-336-7800

	MAIL ADDRESS:	
		STREET 1:		2015 PEEL STREET
		STREET 2:		5TH FLOOR
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H3A 1T8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d32380d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C.&nbsp;20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Report of
Foreign Private Issuer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Rule <FONT STYLE="white-space:nowrap">13a-16</FONT> or
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>under the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;10, 2020 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">001-35203</FONT> </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>THERATECHNOLOGIES INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 Peel
Street, Suite 1100 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Montr&eacute;al, Qu&eacute;bec, Canada </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>H3A 1T8 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of
principal executive offices) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form
<FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F:</FONT> </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form</FONT> <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9746;</FONT> </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by
Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1): </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Note: Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1) only permits the submission in paper of a Form <FONT
STYLE="white-space:nowrap">6-K</FONT> if submitted solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check
mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7): </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Note: Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7) only permits the submission in paper of a Form <FONT
STYLE="white-space:nowrap">6-K</FONT> if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or
legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is not required
to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form <FONT STYLE="white-space:nowrap">6-K</FONT> submission or other Commission filing on EDGAR.
</P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the
information to the Commission pursuant to Rule <FONT STYLE="white-space:nowrap">12g3-2(b)</FONT> under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule
<FONT STYLE="white-space:nowrap">12g3-2(b):</FONT> <FONT STYLE="white-space:nowrap">82-______________.</FONT> </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>THERATECHNOLOGIES INC. </U></B></P>
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release Dated September&nbsp;10, 2020.</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">THERATECHNOLOGIES INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jocelyn Lafond</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jocelyn Lafond</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vice President, Legal Affairs</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: September&nbsp;10, 2020 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d32380dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g32380g25p83.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><B>News Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THERATECHNOLOGIES TO DEVELOP TESAMORELIN FOR THE TREATMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF NASH IN THE GENERAL POPULATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Phase 3 protocol to be filed in Q4 2020; trial expected to begin early 2021 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Clinical study to include HIV cohort </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Montreal, Canada &#150; September&nbsp;10, 2020 &#150; Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company
focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of <FONT STYLE="white-space:nowrap">Non-Alcoholic</FONT>
Steatohepatitis (NASH) in the general population. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;After careful review of our file and discussions with our scientific advisers, we made the
decision to pursue the Phase 3 development of tesamorelin for the treatment of NASH in the general population,&#148; said Mr.&nbsp;Paul L&eacute;vesque, President and Chief Executive Officer, Theratechnologies.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;From 10 years of real-life experience, the safety profile of tesamorelin in HIV patients with lipodystrophy is well established. Based on current
scientific evidence showing a reduction in liver fat and delayed progression of liver fibrosis in patients with HIV infection and NAFLD or NASH, combined with robust intellectual property, a new investigational formulation and the development of a
multi-dose pen injector, we believe that we have a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> candidate for the treatment of NASH in the general population,&#148; added Mr.
L&eacute;vesque. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It was recently published in JCI Insight, a peer-reviewed medical journal, that in
<FONT STYLE="white-space:nowrap">HIV-associated</FONT> NAFLD/NASH, tesamorelin has a positive effect on gene expression related to oxidative phosphorylation, decreased gene expression related to inflammation, tissue repair and cell division while
improving gene expression associated with favorable hepatocellular carcinoma (HCC) prognosis. Based on its unique mode of action, tesamorelin is designed to work upstream to reduce the accumulation of liver fat, which can lead to NASH. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Given that tesamorelin improves critical mechanistic NASH pathways common to both the general population and in people living with HIV, we believe
tesamorelin could bring favorable results in both patient populations,&#148; said Dr.&nbsp;Steven Grinspoon, Professor of Medicine, Harvard Medical School, Chief of the Metabolism Unit at Massachusetts General Hospital and study Principal
Investigator. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;NASH is a silent killer that affects a growing number of people each year worldwide. There is a dire
need for safe and effective treatments for NASH as patients and physicians currently do not have access to any approved drugs. Given its clinical history, recent positive data in patients with <FONT STYLE="white-space:nowrap">HIV-associated</FONT>
NAFLD and its mode of action, we believe tesamorelin has the potential to reverse NASH and NASH related fibrosis in the Phase 3 trial for the management of this serious and deadly condition,&#148; said Dr.&nbsp;Rohit Loomba, Professor of Medicine
(with tenure) in the Division of Gastroenterology, and Adjunct Professor in the Division of Epidemiology at the University of California, San Diego. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Phase 3 clinical trial </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Theratechnologies intends to
submit its Phase 3 study protocol to the United States Food and Drug Administration (FDA) and the European regulatory agencies in the coming weeks. Subject to feedback from the regulatory agencies, the trial would involve approximately 650 patients
with fibrosis scores of 2 and 3 and with a NAS score of at least 4 and also include a cohort of 50 people living with HIV. The enrollment of patients is planned for the first quarter of 2021. Patients will be treated for a period of 18 months. As
per published regulatory guidelines, the primary endpoints will assess NAS score normalisation and absence of worsening of fibrosis stage, or fibrosis improvement <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 1 stage and no worsening of NAS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Theratechnologies intends to use a new investigational formulation of tesamorelin, known as &#147;F8&#148;, for the Phase 3 trial in NASH. In addition, a
supplemental Biologics License Application (sBLA) is expected to be filed with the FDA in early 2022 in <FONT STYLE="white-space:nowrap">HIV-associated</FONT> lipodystrophy using a convenient, multi-dose pen injector currently being developed for
this new formulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The F8 is patent protected in the U.S. until 2033 and until 2034 in major European countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, a notice of allowance was issued by the United States Patent and Trademark Office on a pending US patent application filed by the Massachusetts
General Hospital (MGH) in March 2020 relating to the treatment of hepatic disease using GHRH or analogues thereof.&nbsp;This patent application claims, amongst other things, a method for the treatment of NAFLD or NASH in a patient via the
administration of tesamorelin. Theratechnologies has an exclusive license with the MGH to this patent application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Theratechnologies continues to explore
the filing of additional patent applications in the NAFLD/NASH field. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investigator-initiated study results published in The Lancet HIV </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;11, 2019, results from an investigator-initiated randomized, double-blind, multicenter study assessing the effect of tesamorelin on liver fat
and histology in people living with HIV with NAFLD/NASH were published in The Lancet HIV. This publication followed prior data published in the Journal of Clinical Endocrinology and Metabolism showing that tesamorelin also significantly reduced
ectopic adipose tissue in <FONT STYLE="white-space:nowrap">non-HIV</FONT> patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At baseline, liver biopsies revealed that 43% of patients had liver
fibrosis and 33% had NASH. A total of 61 patients received 2mg of tesamorelin daily or an identical placebo for a period of 12 months. The primary endpoint of the study was a change in hepatic fat fraction. After 12 months of treatment, liver fat in
patients on tesamorelin had decreased by 32% while it had increased by 5% in placebo patients, from baseline, (p=0.02), amounting to a 37% relative reduction in liver fat. Furthermore, 35% of patients in the tesamorelin group returned to liver fat
values below 5% in comparison to only 4% of patients on placebo (p=0.007). The study concluded that only 10.5% of patients in the tesamorelin group experienced progression of liver fibrosis compared to 37.5% in patients receiving a placebo (p=0.04).
Exploratory analyses showed that the higher the baseline NASH score was, the more change was seen among the tesamorelin-treated individuals <FONT STYLE="white-space:nowrap">(r=-0.48,</FONT> P=0.04), whereas a similar relationship was not observed in
the placebo group <FONT STYLE="white-space:nowrap">(r=-0.14,</FONT> P=0.52). The safety profile of tesamorelin in this study was comparable to that observed in HIV patients with lipodystrophy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About NAFLD /NASH </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to the National Institute of
Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, experts estimate that 20&nbsp;percent of Americans with NAFLD have NASH. It is believed that 3 to 12&nbsp;percent of adult Americans have NASH.<SUP
STYLE="font-size:85%; vertical-align:top">1</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NAFLD is an umbrella term for a spectrum of liver conditions that begin with a <FONT
STYLE="white-space:nowrap">build-up</FONT> of hepatic fat, which can set the stage for inflammation that may promote scarring known as fibrosis. Over time, fibrosis can progress to potentially fatal cirrhosis and even a form of liver cancer called
hepatocellular carcinoma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Usually, NAFLD and NASH are silent diseases with few or no symptoms. A patient may not show symptoms even if they
develop&nbsp;cirrhosis&nbsp;due to NASH. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is currently no approved treatment for NAFLD and NASH in the North America and Europe. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/definition-facts#:~:text=Experts%20estimate%20that%20about%2020%20percent%20of%20people%20with%20NAFLD%20have%20NASH.&amp;text=Between%2030%20and%2040%20percent,the%20United%20States%20have%20NASH.
</U> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call Details </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A conference call and webcast will be held on September&nbsp;10, 2020 at 8:30 a.m. (ET) to discuss the announcement. The call will be hosted by Paul
L&eacute;vesque, President and Chief Executive Officer of Theratechnologies, and will include Christian Marsolais, Senior Vice President and Chief Medical Officer, Dr.&nbsp;Steven Grinspoon and Dr.&nbsp;Rohit Loomba. A question and answer period,
open exclusively to financial analysts, will follow their presentation. Investors and members of the media may participate on a listen-only basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To
access the call, please dial <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-877-223-4471</FONT></FONT></FONT> (North America) or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-647-788-4922</FONT></FONT> (International). The conference call will also be webcast live at
<U>https://onlinexperiences.com/Launch/QReg/ShowUUID=38B2592A-4FD1-441C-B11F-A65C5AE94FDC</U><U></U> . An audio replay of the conference call will be available, as of 12:00 (EST) September&nbsp;10, 2020 and until 23:59 (EST) October<U></U>&nbsp;10,
2020, by <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">dialing1-800-585-8367</FONT></FONT> (North America) or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-416-621-4642</FONT></FONT></FONT> (International) and by entering the playback code 6228838. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Theratechnologies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Theratechnologies (TSX: TH)
(NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company&#146;s website at
www.theratech.com, on SEDAR at <U>www.sedar.com</U> and on EDGAR at <U>www.sec.gov</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of
applicable securities laws, that are based on our management&#146;s beliefs and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as &#147;may&#148;, &#147;will&#148;,
&#147;should&#148;, &#147;could&#148;, &#147;would&#148;, &#147;outlook&#148;, &#147;believe&#148;, &#147;plan&#148;, &#147;envisage&#148;, &#147;anticipate&#148;, &#147;expect&#148; and &#147;estimate&#148;, or the negatives of these terms, or
variations of them. The forward-looking statements contained in this press release include, but are not limited to, statements regarding the development of tesamorelin for the treatment of NASH, the timelines related to the filing of a Phase 3 study
protocol, a sBLA for the F8 formulation with regulatory agencies, the enrollment of patients and the study duration, as well statements regarding the development of a multi-dose pen using a new formulation of tesamorelin, expectations about the
common effect of tesamorelin on both the general population and in people living with HIV and expectations about the potential of tesamorelin on the reversal of NASH and NASH related fibrosis in the Phase 3 trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and
uncertainties, many of which are beyond Theratechnologies&#146; control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These assumptions include but are not
limited to, the following: tesamorelin will be shown as a safe and effective drug for the treatment of NASH in the general population, tesamorelin data and results monitored to date will continue to be observed in the Phase&nbsp;3 trial, the various
timelines set forth in this press release will be met, the Phase 3 study protocol will be approved by both the FDA and the European regulatory agencies, the F8 formulation will be approved for use by the FDA for the treatment of lipodystrophy and by
the FDA and the EMA in connection with the Phase 3 trial, we will succeed in enrolling a sufficient number of patients to conduct the Phase 3 trial, the development of the multi-dose injection pen will be successful, and we will have enough funds to
conduct the Phase 3 development of tesamorelin in the general population suffering from NASH and to execute on our business plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The risks and
uncertainties include, among others, the risk that tesamorelin does not prove to be a safe and effective drug for the treatment of NASH, that the FDA and European regulatory agencies do not allow us to proceed with a Phase 3 trial without conducting
a Phase 2b or earlier study in the general NASH population, that we do not meet the endpoints of the Phase 3 trial, that we are unable to enroll a sufficient number of patients to show clinical benefits from the use of tesamorelin, that unknown side
effects of tesamorelin are discovered, that our intellectual property is challenged and held to be invalid or infringing upon third parties&#146; intellectual property, that the development of a multi-dose pen is not successful, that the F8
formulation is not approved by the FDA for use in lipodystrophy or by the FDA and the EMA in connection with the Phase 3 trial, that we are unable to finance the Phase 3 trial and our business plan, that competing drugs are or may become available
and more successful, that performance of third-party suppliers and manufacturers may be deficient, that expenses, revenues and capital requirements vary from our estimates, that conditions may be imposed by regulatory authorities on the marketing
approvals for our products, that we are unable to adequately service the markets for our products, and a poor rate and degree of market acceptance of our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We refer potential investors to the &#147;Risk Factors&#148; section of our annual information form dated February&nbsp;24, 2020 and to our Form <FONT
STYLE="white-space:nowrap">40-F</FONT> dated February&nbsp;25, 2020 filed on EDGAR for additional risks regarding the conduct of our business and Theratechnologies. The reader is cautioned to consider these and other risks and uncertainties
carefully and not to put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that
date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We undertake no obligation to update or revise the information contained in this press release, whether as a
result of new information, future events or circumstances or otherwise, except as may be required by applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-30- </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For media inquiries: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Denis Boucher </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Communications and Corporate Affairs </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">514-336-7800</FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For investor inquiries: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leah Gibson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Director, Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-356-1900</FONT></FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g32380g25p83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g32380g25p83.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  (" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @,# @(# @(" P0# P,#! 0$ @,$! 0$! ,$! ,! @(" @(" @(" @,"
M @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# __$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MI'#Y16&W(.#G!QU["6WR\T(N7X+[]?R,I34---]%Y6O?9V_K7H/$W PN"02
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M"G6I>UDU!M))V3DM$[:VO;S/6<*=3DDHJ+BTUIVLUV.JB01@8Z!0H4# &.F
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MST QGIQ7SK3IN-&,%SRU;NK6N^M^R/H>=3O5=1^SCHE;K9+M?=G@?QR_9X\
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MFM7_ (3T6^\1+I*:Y=Z=87.IIH5W)J&C)>3V-K+.=,O91NN;)I':2-]TJ[9
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M=4ISC)5*C>BCI%:O5&=??!V6?1/C3\0/C=KMI:ZE\0/"$.DZK9^&;>^U+2/
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M^@;?(7:HP,=#D=\$=^>^>])QC!QM'KTN"_(4 #';:,#MC\/PK0!: "@ H *
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6  ,8'I1M\BDWUBH]DG?3Y;#Z!G__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
